• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期和晚期卵巢癌及卵巢良性肿瘤患者血清、腹水和囊液中的促炎及免疫抑制细胞因子

Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.

作者信息

Nowak Marek, Glowacka Ewa, Szpakowski Marian, Szyllo Krzysztof, Malinowski Andrzej, Kulig Andrzej, Tchorzewski Henryk, Wilczynski Jan

机构信息

Department of Gynecologic Surgery, Polish Mother's Memorial Hospital - Research Institute, Poland.

出版信息

Neuro Endocrinol Lett. 2010;31(3):375-83.

PMID:20588232
Abstract

OBJECTIVE

To analyze the profiles of interleukin-2 (IL-2), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status. We also estimated serum cytokines as biomarkers to distinguish preoperatively between malignant or benign character of tumors.

DESIGN

Prospective study.

SETTING

Tertiary referral hospital.

POPULATION

51 women with epithelial ovarian cancer, 26 with benign ovarian tumors of epithelial origin and 21 healthy controls.

METHODS

The levels of cytokines were measured using ELISA sets.

RESULTS

We did not found differences in the levels of IFN-gamma, TNF-alpha and IL-2 in all fluids isolated from patients with malignant or benign tumors. Women with advanced cancer had significantly higher serum IL-6, IL-10 and TGF-beta1 levels than women with early stages or benign tumors. Moreover, women with very advanced cancer in whom the optimal cytoreduction was disabled had the highest serum levels of IL-10, TGF-beta1 and IL-8. The concentrations of IL-6 and IL-8 were higher in ascites of cancer patients than in ascites of women with benign tumors. The areas under curves constructed for the selected cutoff serum cytokines levels (AUC-ROC) showed good predictive values for IL-6 (0.87), IL-10 (0.836) and IL-8 (0.797).

CONCLUSIONS

Our results indicate on intensified inflammatory process in women with ovarian cancer (accompanied by their immunosuppression). Preoperative analysis of serum IL-6, IL-10 and IL-8 may improve the differential diagnosis of ovarian tumors.

摘要

目的

分析卵巢癌或卵巢良性肿瘤女性患者血清及肿瘤微环境(囊液、腹水)中白细胞介素-2(IL-2)、IL-6、IL-8、IL-10、肿瘤坏死因子-α(TNF-α)、转化生长因子-β1(TGF-β1)和干扰素-γ(IFN-γ)的水平,以发现其免疫状态的差异。我们还评估血清细胞因子作为生物标志物在术前区分肿瘤恶性或良性特征的作用。

设计

前瞻性研究。

地点

三级转诊医院。

研究对象

51例上皮性卵巢癌女性患者、26例上皮性卵巢良性肿瘤女性患者和21例健康对照者。

方法

使用酶联免疫吸附测定试剂盒检测细胞因子水平。

结果

我们未发现恶性或良性肿瘤患者分离出的所有体液中IFN-γ、TNF-α和IL-2水平存在差异。晚期癌症女性患者的血清IL-6、IL-10和TGF-β1水平显著高于早期或良性肿瘤女性患者。此外,无法进行最佳肿瘤细胞减灭术的极晚期癌症女性患者的血清IL-10、TGF-β1和IL-8水平最高。癌症患者腹水中IL-6和IL-8的浓度高于良性肿瘤女性患者的腹水。根据选定的血清细胞因子水平临界值构建的曲线下面积(AUC-ROC)显示,IL-6(0.87)、IL-10(0.836)和IL-8(0.797)具有良好的预测价值。

结论

我们的结果表明卵巢癌女性患者存在炎症过程加剧(伴有免疫抑制)。术前分析血清IL-6、IL-10和IL-8可能会改善卵巢肿瘤的鉴别诊断。

相似文献

1
Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.早期和晚期卵巢癌及卵巢良性肿瘤患者血清、腹水和囊液中的促炎及免疫抑制细胞因子
Neuro Endocrinol Lett. 2010;31(3):375-83.
2
Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.腹水中白细胞介素-1受体拮抗剂(IL-1 RA)浓度降低与卵巢癌患者总生存期的显著改善相关。
Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.
3
[-Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma-].
Geburtshilfe Frauenheilkd. 1996 Feb;56(2):83-7. doi: 10.1055/s-2007-1022247.
4
Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells.外周血单个核细胞与自体卵巢癌细胞或良性卵巢肿瘤细胞相互作用过程中细胞因子的产生。
Scand J Immunol. 2010 Feb;71(2):91-8. doi: 10.1111/j.1365-3083.2009.02350.x.
5
Expression of IL-10 in patients with ovarian carcinoma.白细胞介素-10在卵巢癌患者中的表达。
Anticancer Res. 2006 Mar-Apr;26(2C):1715-8.
6
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.血清细胞因子谱作为卵巢癌诊断和预后工具:白细胞介素7的潜在作用
Clin Cancer Res. 2007 Apr 15;13(8):2385-91. doi: 10.1158/1078-0432.CCR-06-1828.
7
Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.良性和(交界性)恶性卵巢肿瘤患者的囊液、血清和肿瘤中的Fas及Fas配体
Int J Oncol. 2005 Feb;26(2):379-84.
8
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.晚期卵巢癌腹水中NK T样CD3+CD56+细胞及CD4+CD25+(hi)调节性T细胞与VEGF和TNFα的相关性:与接受一线铂类化疗患者的铂耐药及预后的关系
Gynecol Oncol. 2008 Feb;108(2):421-7. doi: 10.1016/j.ygyno.2007.10.018. Epub 2007 Nov 26.
9
Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.上皮性卵巢癌中免疫抑制细胞因子谱的评估
J Obstet Gynaecol Res. 2009 Apr;35(2):212-8. doi: 10.1111/j.1447-0756.2008.00935.x.
10
Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.卵巢癌及非卵巢良恶性疾病患者血清、胸腔积液和腹水CA - 125水平的比较研究
Gynecol Oncol. 2002 Apr;85(1):108-13. doi: 10.1006/gyno.2001.6575.

引用本文的文献

1
Exploring potential methylation markers for ovarian cancer from cervical scraping samples.从宫颈刮片中探索卵巢癌的潜在甲基化标志物。
Hum Genomics. 2025 May 17;19(1):56. doi: 10.1186/s40246-025-00763-4.
2
Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization.通过 TGF-β1/IL-15 极化产生抑制性 NK 细胞亚群。
J Immunol. 2024 Jun 15;212(12):1904-1912. doi: 10.4049/jimmunol.2300834.
3
The complex role of IL-10 in malignant ascites: a review.IL-10 在恶性腹水的复杂作用:综述。
Cancer Immunol Immunother. 2024 Jan 27;73(2):32. doi: 10.1007/s00262-023-03616-y.
4
Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer.叶酸受体靶向光动力疗法:刺激腹腔卵巢癌抗肿瘤免疫反应的新方法。
Int J Mol Sci. 2023 Jul 10;24(14):11288. doi: 10.3390/ijms241411288.
5
Spatial Heterogeneity in Cytoskeletal Mechanics Response to TGF-β1 and Hypoxia Mediates Partial Epithelial-to-Meshenchymal Transition in Epithelial Ovarian Cancer Cells.细胞骨架力学对转化生长因子-β1和缺氧反应的空间异质性介导上皮性卵巢癌细胞的部分上皮-间质转化
Cancers (Basel). 2023 Jun 14;15(12):3186. doi: 10.3390/cancers15123186.
6
Development of a machine learning-based signature utilizing inflammatory response genes for predicting prognosis and immune microenvironment in ovarian cancer.利用炎症反应基因开发基于机器学习的特征用于预测卵巢癌的预后和免疫微环境
Open Med (Wars). 2023 Jun 2;18(1):20230734. doi: 10.1515/med-2023-0734. eCollection 2023.
7
Analysis of the Occurrence of Predicative Factors of Chronic Fatigue in Female Patients with Cancer of the Reproductive Organs with Respect to Stage of Treatment.分析治疗阶段的女性生殖器官癌症患者慢性疲劳预测因素的发生情况。
Int J Environ Res Public Health. 2023 Feb 20;20(4):3732. doi: 10.3390/ijerph20043732.
8
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses.联合表达TNFR2的调节性T细胞和白细胞介素-6作为高级别浆液性卵巢癌肿块的卓越诊断生物标志物。
Cancers (Basel). 2023 Jan 21;15(3):667. doi: 10.3390/cancers15030667.
9
The multifaced role and therapeutic regulation of autophagy in ovarian cancer.自噬在卵巢癌中的多面作用及治疗调控
Clin Transl Oncol. 2023 May;25(5):1207-1217. doi: 10.1007/s12094-022-03045-w. Epub 2022 Dec 19.
10
Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib.莪术醇靶向PAX8抑制卵巢癌细胞迁移和侵袭并增强尼拉帕利的化疗敏感性
J Oncol. 2022 May 2;2022:3941630. doi: 10.1155/2022/3941630. eCollection 2022.